(Q37931268)

25 August 2017

1 reference

title

Therapeutic pipeline for soft-tissue sarcoma (English)

1 reference

25 August 2017

9

1 reference

25 August 2017

8

Isabelle Ray-Coquard

0 references

Intidhar Labidi-Galy

object named as

Sana Intidhar Labidi-Galy

2

0 references

Pierre Etienne Heudel

3

object named as

Pierre Heudel

1 reference

25 August 2017

7

Laurent Alberti

1 reference

Philippe Alexandre Cassier

25 August 2017

1

object named as

Philippe A Cassier

1 reference

25 August 2017

Aurélie Dutour

4

1 reference

25 August 2017

Pierre Méeus

5

1 reference

25 August 2017

Maria Chelghoum

6

1 reference

25 August 2017

language of work or name

English

0 references

publication date

13 September 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

16

1 reference

25 August 2017

page(s)

2479-2491

1 reference

Soft-tissue sarcomas in adults

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Mechanisms of sarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Trends in survival for patients with metastatic soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Imatinib mesylate for the treatment of gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Flushing oral oncology drugs down the toilet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Features predicting sentinel lymph node positivity in Merkel cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Alveolar soft-part sarcomas; structurally characteristic tumors of uncertain histogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Angiogenesis-promoting gene patterns in alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Response to sunitinib malate in advanced alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Prognostic significance of activated AKT expression in soft-tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Antiangiogenesis agents in the treatment of soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Well-differentiated and dedifferentiated liposarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Hedgehog signalling in cancer formation and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Activating Smoothened mutations in sporadic basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Identification of PATCHED mutations in medulloblastomas by direct sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Smoothened as a new therapeutic target for human osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.604633

10.1517/14656566.2011.604633

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference